Merck & Co., Inc.
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.6%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 7 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
13 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $526,407,164 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedTrimmed
Positions the filer reducedNew Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | 1,739,768 | $12,804,692 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| — | 1,473,240 | $0 | ||
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PSNL |
Personalis, Inc.
Healthcare
|
Held | 14,044,943 | $188,202,236 | 35.75% | |
| MRNA |
Moderna, Inc.
Healthcare
|
Held | 2,308,190 | $161,642,545 | 30.71% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Held | 772,165 | $88,544,160 | 16.82% | |
| AKTS |
Aktis Oncology, Inc.
Healthcare
|
Held | 952,844 | $30,710,162 | 5.83% | |
| EIKN |
Eikon Therapeutics, Inc.
Healthcare
|
Held | 1,666,666 | $21,749,991 | 4.13% | |
| TRDA |
Entrada Therapeutics, Inc.
Healthcare
|
NEW | 1,739,768 | $12,804,692 | 2.43% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
Held | 272,351 | $9,042,053 | 1.72% | |
| ALEC |
Alector, Inc.
Healthcare
|
Held | 3,545,719 | $7,126,895 | 1.35% | |
| EVAX |
Evaxion A/S
Healthcare
|
Held | 1,214,126 | $3,763,790 | 0.71% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Held | 93,414 | $1,716,015 | 0.33% | |
| XLO |
Xilio Therapeutics, Inc.
Healthcare
|
Held | 105,982 | $1,015,307 | 0.19% | |
| HURA |
TuHURA Biosciences, Inc.
Healthcare
|
Held | 19,445 | $45,501 | 0.01% | |
| NEUP |
Neuphoria Therapeutics Inc.
Healthcare
|
Held | 10,027 | $43,817 | 0.01% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.